Melatonin modulates aromatase activity in MCF-7 human breast cancer cells

Samuel Cos1, Carlos Martínez-Campa, Maria D Mediavilla

  • 1Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, Santander, Spain.

Insights

Melatonin, a hormone, inhibits breast cancer cell growth by reducing aromatase activity and expression. This indoleamine offers potential for preventing and treating hormone-dependent mammary cancers.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Melatonin is known to inhibit breast cancer cell growth, primarily through antiestrogenic mechanisms.
  • The effect of melatonin on local estrogen synthesis, specifically aromatase activity, in breast cancer cells remains largely unexamined.

Purpose of the Study:

  • To investigate whether melatonin modulates aromatase activity and estrogen biosynthesis in MCF-7 breast cancer cells.
  • To determine the impact of melatonin on testosterone-induced proliferation in MCF-7 cells, which relies on local estrogen production.

Main Methods:

  • MCF-7 cells were cultured with testosterone in estradiol-free media.
  • Aromatase activity was measured using the tritiated water release assay.
  • Gene expression of aromatase was analyzed using RT-PCR.

Main Results:

  • Melatonin (1 nM) counteracted testosterone-induced proliferation in MCF-7 cells.
  • Melatonin significantly reduced basal and stimulated aromatase activity in MCF-7 cells.
  • Melatonin downregulated aromatase expression at the transcriptional level in MCF-7 cells.

Conclusions:

  • Melatonin, at physiological concentrations, inhibits both the activity and expression of aromatase in MCF-7 breast cancer cells.
  • This inhibition of local estrogen biosynthesis, combined with known antiestrogenic effects, positions melatonin as a potential therapeutic agent for hormone-dependent breast cancer.